Published in Liver Transpl on July 01, 2005
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver (2015) 1.23
2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol (2015) 1.14
Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. HPB (Oxford) (2008) 1.12
Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol (2013) 0.94
Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol (2013) 0.92
Actual therapeutic efficacy of pre-transplant treatment on hepatocellular carcinoma and its impact on survival after salvage living donor liver transplantation. J Gastroenterol (2009) 0.90
Prevention of recurrence after curative treatment for hepatocellular carcinoma. Surg Today (2012) 0.90
Hepatocellular Carcinoma and Liver Transplantation: State of the Art. J Clin Transl Hepatol (2014) 0.90
Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma. AJR Am J Roentgenol (2011) 0.89
Role of surgical resection for multiple hepatocellular carcinomas. World J Gastroenterol (2013) 0.88
The management of patients awaiting liver transplantation. Nat Rev Gastroenterol Hepatol (2009) 0.86
Current status of therapy for hepatocellular carcinoma. Therap Adv Gastroenterol (2009) 0.84
Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation. World J Gastroenterol (2007) 0.83
Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol (2013) 0.83
Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol (2015) 0.82
Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis. World J Gastroenterol (2015) 0.82
Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation: a retrospective study. Int J Hepatol (2011) 0.82
Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival. World J Gastroenterol (2015) 0.81
Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand? World J Gastroenterol (2014) 0.81
Impact of transarterial therapy in hepatitis C-related hepatocellular carcinoma on long-term outcomes after liver transplantation. Am J Clin Oncol (2012) 0.79
Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World J Hepatol (2015) 0.79
Radiofrequency ablation for viable hepatocellular carcinoma around retained iodized oil after transcatheter arterial chemoembolization: usefulness of biplane fluoroscopy plus ultrasound guidance. Korean J Radiol (2012) 0.79
Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol (2015) 0.79
Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol (2014) 0.78
Bridge treatments of hepatocellular carcinoma in cirrhotic patients submitted to liver transplantation. Dig Dis Sci (2008) 0.76
Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list. Cardiovasc Intervent Radiol (2010) 0.76
Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol (2016) 0.76
Preoperative portal venous and hepatic arterial embolization of tumor. Semin Intervent Radiol (2008) 0.75
Revisiting the role of pathological analysis in transarterial chemoembolization-treated hepatocellular carcinoma after transplantation. World J Gastroenterol (2014) 0.75
HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? Visc Med (2016) 0.75
Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC. PLoS One (2013) 0.75
Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma. Sci Rep (2017) 0.75
A case of hepatocellular carcinoma in the caudate lobe successfully treated by transcatheter arterial chemoembolization using drug-eluting beads. Korean J Hepatol (2010) 0.75
Independent prognostic factors for posttransplant survival in hepatocellular carcinoma patients undergoing liver transplantation. Cancer Med (2016) 0.75
Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation. Transl Gastroenterol Hepatol (2016) 0.75
Bridging patients with hepatocellular cancer waiting for liver transplant: all the patients are the same? Transl Gastroenterol Hepatol (2017) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology (2005) 5.93
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat Immunol (2008) 4.78
Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med (2014) 4.70
The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol (2013) 4.05
Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology (2007) 3.75
Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology (2010) 3.22
Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology (2006) 3.19
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology (2006) 3.09
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun (2013) 3.06
Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One (2011) 2.84
Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology (2002) 2.56
Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology (2011) 2.54
Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg (2011) 2.42
Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol (2012) 2.39
Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol (2006) 2.37
Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg (2015) 2.36
Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology (2005) 2.33
Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg (2009) 2.30
Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology (2002) 2.21
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology (2006) 2.21
Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial. Ann Intern Med (2009) 2.16
C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem (2002) 2.16
Laparoscopic versus open left lateral hepatic lobectomy: a case-control study. J Am Coll Surg (2003) 2.13
Laparoscopic liver resection facilitates salvage liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg (2009) 2.12
Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: midterm results and perspectives. Ann Surg (2006) 2.10
Kidney and recipient weight incompatibility reduces long-term graft survival. J Am Soc Nephrol (2010) 2.08
Optimizing outflow in piggyback liver transplantation without caval occlusion: the three-vein technique. Liver Transpl (2011) 2.07
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology (2002) 2.06
WHO classification of alveolar echinococcosis: principles and application. Parasitol Int (2005) 2.06
Laparoscopic hepatectomy for hepatocellular carcinoma: a European experience. J Am Coll Surg (2010) 2.05
Surgical management of liver hydatid disease: subadventitial cystectomy versus resection of the protruding dome. World J Surg (2014) 2.04
Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology (2012) 2.01
Laparoscopic major hepatectomy: an evolution in standard of care. Ann Surg (2009) 2.01
Impact of age over 75 years on outcomes after pancreaticoduodenectomy. J Surg Res (2012) 2.00
[Assessment of hepatic fibrosis: what is the role of non-invasive markers in 2003?]. Gastroenterol Clin Biol (2003) 1.99
Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg (2013) 1.98
Transdiaphragmatic extrapericardial approach of the inferior vena cava. J Am Coll Surg (2013) 1.97
Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology (2007) 1.94
Laparoscopic liver resection for subcapsular hepatocellular carcinoma complicating chronic liver disease. Arch Surg (2003) 1.92
Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology (2004) 1.92
Positioning trocars for performing sleeve gastrectomy. Points of controversy. Obes Surg (2015) 1.90
Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr (2006) 1.87
Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl (2006) 1.86
Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology (2010) 1.85
Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". Am J Gastroenterol (2009) 1.83
Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: results of a multicentric study. Dis Colon Rectum (2011) 1.82
Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: an analysis of 259 episodes. Liver Transpl (2010) 1.81
Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant (2005) 1.79
Small-for-size partial liver graft in an adult recipient; a new transplant technique. Lancet (2002) 1.78
Two cases of spontaneous regression of multicentric hepatocellular carcinoma after intraperitoneal rupture: possible role of immune mechanisms. Eur J Gastroenterol Hepatol (2004) 1.78
Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: a pilot study. Liver Transpl (2006) 1.74
Minimally invasive liver resection for metastatic colorectal cancer: a multi-institutional, international report of safety, feasibility, and early outcomes. Ann Surg (2009) 1.74
Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol (2004) 1.71
Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood (2011) 1.71
The role of delayed 18F-FDG PET imaging in the follow-up of patients with alveolar echinococcosis. J Nucl Med (2013) 1.70
Laparoscopic liver resection-understanding its role in current practice: the Henri Mondor Hospital experience. Ann Surg (2009) 1.70
Type II endoleaks after endovascular repair of abdominal aortic aneurysm are not always a benign condition. J Vasc Surg (2013) 1.68
Mangafodipir prevents liver injury induced by acetaminophen in the mouse. J Hepatol (2003) 1.67
Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology (2003) 1.65
Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection : an observational multicenter study. Liver Transpl (2007) 1.64
The learning curve in laparoscopic liver resection: improved feasibility and reproducibility. Ann Surg (2009) 1.63
Renal function, efficacy and safety postconversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study. Transpl Int (2012) 1.62
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol (2006) 1.58